Riluzole, an FDA-approved drug for Lou Gehrig's Disease has been shown to slow the growth of melanoma. A phase 0 (first in human) trial on people with late stages of melanoma conducted by investigators at Rutgers shows that Riluzole slowed the growth of melanoma in enough patients to warrant further studies.
Comments
Comments are closed for this post.
